# US 2008/0287480 A1 · Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287480 A1
- Document ID: US20080287480A1
- Status: Published application
- Kind: A1
- Application number: 11/995,983
- Filed: 2006-07-18
- Published: 2008-11-20
- Earliest claimed: 2005-07-28
- Assignees: Chiesi Farmaceutici S.p.A.
- Inventors: Paolo Chiesi; Gino Villetti
- Web page: https://patentgrep.com/patent/US20080287480A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various types of pain and/or for inhibiting the development of tolerance, and/or physical dependence on a narcotic analgesic substance.

## Claims

### Claim at position 1

1: A medicament comprising a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes (a NMDA/MAO blocker) and a narcotic analgesic substance wherein the two substances are administrated simultaneously.

### Claim at position 2 (depends on 1)

2: The medicament according to claim 1 wherein the NMDA/MAO blocker and the narcotic analgesic substance are present in a fixed combination.

### Claim at position 3 (depends on 1)

3: The medicament according to claim 1 wherein the NMDA/MAO blocker is a compound represented by the general formula I:
wherein:
R is hydrogen or C1-C4 alkyl groups;
R1 is hydrogen, C1-C10 alkyl or optionally acylated C1-C4 hydroxyalkyl wherein the acylated C1-C4 hydroxyalkyl is selected from the group of acetyloxy C1-C4 alkyl, propanoyloxy C1-C4 alkyl, 2-methylpropanoyloxy C1-C4 alkyl, and benzoyloxy C1-C4 alkyl;
R2 is hydrogen; C1-C10 alkyl; phenyl; phenyl C1-C10 alkyl; and pharmaceutically acceptable salts thereof.

### Claim at position 4 (depends on 3)

4: The medicament according to claim 3 wherein R, R1 and R2 are hydrogen and the compound is N-2(indanyl)-glycinamide.

### Claim at position 5 (depends on 1)

5: The medicament according to claim 1 wherein the analgesic narcotic substance is selected from the group consisting of fentanyl, hydrocodone, hydromorphone, meperidine, morphine, oxymorphone, phenyltazocine and tramadol, or pharmaceutically acceptable salts thereof such as hydrochloride, sulphate, citrate, lactate and tartrate.

### Claim at position 6 (depends on 5)

6: The medicament according to claim 5 wherein the analgesic narcotic substance is morphine hydrochloride or sulphate.

### Claim at position 7

7: A pharmaceutical composition comprising therapeutically effective amounts of a NMDA/MAO blocker and a narcotic analgesic substance, optionally together with at least one pharmaceutically acceptable carrier or diluent.

### Claim at position 8

8: A kit comprising: a) a therapeutically effective amount of a NMDA/MAO blocker in a pharmaceutically acceptable carrier or diluent in a first unit dosage form; b) a therapeutically effective amount of a narcotic analgesic substance or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and c) a container for containing said first and second dosage forms in a unique packaging.

### Claim at position 9

9: A method for the treatment of subjects suffering from moderate to severe pain conditions, acute or chronic, whether the pain is of neuropathic or inflammatory type or caused by different nociceptive stimuli comprising administering simultaneously a combination of a NMDA/MAO blocker and a narcotic analgesic substance.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the combination is a fixed combination.

### Claim at position 11 (depends on 9)

11: The method according to claim 9 wherein the NMDA/MAO blocker is a compound represented by the general formula I:
wherein:
R is hydrogen or C1-C4 alkyl groups;
R1 is hydrogen, C1-C10 alkyl or optionally acylated C1-C4 hydroxyalkyl wherein the acylated C1-C4 hydroxyalkyl is selected from the group of acetyloxy C1-C4 alkyl, propanoyloxy C1-C4 alkyl, 2-methylpropanoyloxy C1-C4 alkyl, and benzoyloxy C1-C4 alkyl;
R2 is hydrogen; C1-C10 alkyl; phenyl; phenyl C1-C10 alkyl; and pharmaceutically acceptable salts thereof.

### Claim at position 12 (depends on 11)

12: The method according to claim 11 wherein R, R1 and R2 are hydrogen and the compound is N-2(indanyl)-glycinamide.

### Claim at position 13 (depends on 9)

13: The method according to claim 9 wherein the pain conditions are mixed pain conditions characterized by the presence of acute and chronic pain components.

### Claim at position 14 (depends on 13)

14: The method according to claim 13 wherein the pain is a neuropathic pain refractory to the treatment with narcotic analgesic substances.
